Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to advancing their pipeline. They did not provide detailed financial guidance for the upcoming quarters.
Management did not provide specific updates on revenue or guidance.
The focus remains on ongoing clinical trials and product development.
Xenon Pharmaceuticals did not report specific revenue figures, and the EPS loss was in line with expectations. The stock rose by 1.59%, likely reflecting investor optimism about the company's ongoing clinical trials and product development efforts despite the lack of detailed financial guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Jul 31, 2017